Pontificia Universidad Católica de Chile

Running trials

• Enrolling by invitation

  Fibromyalgia and Functional Impact: the Complementary Role of Neural Mobilization.

  NCT07825506· Pontificia Universidad Catolica de Chile· Source

• Recruiting

  A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

  NCT07634471· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Mediterranean Diet and Time-Restricted Feeding in Ulcerative Colitis Remission

  NCT07752446· Pontificia Universidad Catolica de Chile· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

  NCT07227597· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

  NCT07378644· Phase 2/3· Skyhawk Therapeutics, Inc.· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

  NCT07058077· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

  NCT07011745· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

  NCT06833073· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

  NCT06780137· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  PROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel Disease

  NCT06758024· Pontificia Universidad Catolica de Chile· Source

• Active, not recruiting

  Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

  NCT06428396· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  NCT06561386· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease

  NCT06584383· InSightec· Source

• Active, not recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

  NCT06459180· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

  NCT06353386· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Non-pharmacological Prevention of POD in Frailty Elderly Undergoing Elective Surgery Applied by Nursing Teams

  NCT05993754· Pontificia Universidad Catolica de Chile· Source

• Active, not recruiting

  A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

  NCT06305767· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

  NCT07159750· Hospital Universitari Vall d'Hebron Research Institute· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

  NCT06132958· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

  NCT06077760· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

  NCT06063967· Phase 3· AbbVie· Source

• Active, not recruiting

  A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

  NCT06097364· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

  NCT06074588· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Recruiting

  Early Inflammatory Bowel Disease Progression

  NCT06756100· Pontificia Universidad Catolica de Chile· Source

• Active, not recruiting

  A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

  NCT05766501· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

  NCT05609968· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

  NCT05173987· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

• Active, not recruiting

  Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

  NCT04768062· Phase 3· NS Pharma, Inc.· Source

• Recruiting

  Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach

  NCT04022109· University of Latvia· Source

• Active, not recruiting

  Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

  NCT03553836· Phase 3· Merck Sharp & Dohme LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Ulcerative colitis3 recruiting
• Bladder cancer2 recruiting
• Crohn's disease2 recruiting
• Ovarian cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Alzheimer disease1 recruiting
• Endometrial cancer1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Fibromyalgia1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Heart failure1 recruiting
• Huntington's disease1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Obesity1 recruiting
• Primary biliary cholangitis1 recruiting

Closed trials

• Completed

  Adding Group-Based Pain Neuroscience Education to a Community Exercise Program for Older Women With Knee Osteoarthritis

  NCT07565298· Pontificia Universidad Catolica de Chile· Source

• Completed

  Reliability and Validity of Outcome Measures for Pain in Multiple Sclerosis

  NCT05742152· Hasselt University· Source

• Completed

  Chronic Pain in the General Population of Chile

  NCT06353100· Pontificia Universidad Catolica de Chile· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

  NCT05064059· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Airborne Preventive Measures to Reduce New TB Infections in Household Contacts

  NCT04938596· Pontificia Universidad Catolica de Chile· Source

• Completed

  Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients

  NCT04896242· Pontificia Universidad Catolica de Chile· Source

• Completed

  A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

  NCT04148911· Phase 3· Hoffmann-La Roche· Source

• Completed

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

  NCT04003636· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population

  NCT04019808· Fundación para la Investigación del Hospital Clínico de Valencia· Source

• Completed

  Advanced GC Multi-omic Characterization in EU and CELAC Populations

  NCT04015466· Fundación para la Investigación del Hospital Clínico de Valencia· Source

• Completed

  Gastric Cancer Risk Factors Associated With EU and CELAC Populations

  NCT03957031· Fundación para la Investigación del Hospital Clínico de Valencia· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

  NCT03834519· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

  NCT03829319· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

  NCT03820986· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

  NCT03740165· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

  NCT03675737· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

  NCT03260894· Phase 3· Incyte Corporation· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

  NCT03221426· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

  NCT03142334· Phase 3· Merck Sharp & Dohme LLC· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Fatty liver disease (MASLD/MASH)39 works · 1 trial
• Hepatitis C12 works · 0 trials
• Down syndrome7 works · 0 trials
• Eosinophilic oesophagitis5 works · 0 trials
• Epidermolysis bullosa5 works · 0 trials